FDA-Approved HIV Medications

The Latest

Promo Image

Out of the Lab: A New Target and a New Agent From Gilead

This space reviews early laboratory findings from the Journal of Virology that shows scientists at work uncovering new ways to think about -- and ultimately beat the virus.

Betting on Betulinic Acid

In the January issue of the Journal of Virology, ...

Promo Image

Pharmacokinetic Interactions of 908

All the pieces are falling into place before the expected FDA approval of GW433908, better known as "908," later this year. There were several presentations at this ICAAC clarifying several issues regarding the pharmacokinetic (PK) parameters and int...

Promo Image

High Dose of Vitamin C Significantly Reduces Indinavir Levels in Pilot Study


Disturbingly few studies to date have focused on the potential impact of vitamins, minerals, herbal medicines and other supplements on the blood plasma levels of HIV antiretrovirals, particularly protease inhibitors. There are any number ...

Promo Image

Atazanavir/Tenofovir Combo Should Be Boosted With Ritonavir

Dear Healthcare Provider,

Bristol-Myers Squibb Company would like to make clinicians caring for HIV-infected patients aware of important new pharmacokinetic (PK) data concerning the coadministration of ReyatazTM (atazanavir sulfate) and Viread® (ten...

Promo Image

Using Genotypic Inhibitory Quotient to Measure Response to Boosted-Amprenavir Regimen

Efficacy of Ritonavir/Amprenavir-Containing Regimen in HIV-1 Protease Inhibitor-Experienced Patients and Predictivity of the Delta Viral Load Values Up to Week 24 Using Genotypic Inhibitory Quotient (Oral 165) Authored by A.G. Marcelin, C. Lamo...

Promo Image

Protease Inhibitors and Severe Adverse Events

Incidence and Risk Factors for Severe Adverse Events in a Prospective Cohort of HIV-Infected Adults Started on a Protease Inhibitor-Containing Therapy (Oral 56) Authored by X. Duval, V. Journot, T. May, C. Charlois, A. Waldner, C. Merle de Boev...

Promo Image

Switch to Nevirapine From Protease Inhibitor Lowers Triglycerides and Maintains Viral Load Suppression

Long-Term Efficacy and Safety of Protease Inhibitor Switching to Nevirapine in HIV Patients With Undetectable Viral Load (Poster 590) Authored by P. Gil, M. Górgolas, V. Estrada, A. Arranz, P. Rivas, C. Yera, R. García Delgado, J.J. Granizo, M....

Promo Image

No Interactions Between Tipranavir/Ritonavir and Efavirenz, Tenofovir and AZT

Standard Doses of Efavirenz (EFV), Zidovudine (ZDV), Tenofovir (TDF), and Didanosine (ddI) May Be Given With Tipranavir/Ritonavir (TPV/r) (Poster 865) Authored by P.J. Roszko, K. Curry, B. Brazina, A. Cohen, E.L. Turkie, J.P. Sabo, T.R. MacGreg...

Promo Image

Older PIs Linked to Early Coronary Artery Disease

Reported series of patients have suggested that HIV-infected patients are at an increased risk of coronary artery disease (CAD), linked to the hyperlipidemia and insulin resistance associated with protease-inhibitor therapy. However, necropsy studies...

Promo Image
People Who Use Drugs

Risky Cocktails

Recreational/Street Drug/Abused PrescriptionHIV/Prescription MedicationInteractionCommentsAlcoholABC/Ziagen/AbacavirIncreases ABC levels in blood. One study observed a 41% increase in ABC.1ABC is metabolized by alcohol dehydrogenase, therefore increa...